Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filipa Lynce

Showing results (81-90 of 96) with videos related to

Pageof 10
Sort By:
European Journal of Cancer (Oxford, England : 1990)|November 1, 2024
Immune checkpoint inhibitors for patients with metastatic triple-negative inflammatory breast cancer (INCORPORATE): An international cohort studyCarmine Valenza, Dario Trapani, Paola Zagami, et al.
Journal of the National Cancer Institute|March 31, 2025
Development of a Multi-Institutional Dataset to Validate a Novel Inflammatory Breast Cancer Diagnostic ScoreFilipa Lynce, Samuel M Niman, Megumi Kai, et al.
JCO Global Oncology|December 20, 2024
Awareness, Knowledge, and Treatment Patterns of Nonmetastatic Inflammatory Breast Cancer in Low- and Middle-Income Countries: The BRIDGES StudyIlana Schlam, Kelly A Hirko, Daniela Shveid, et al.
Nature Communications|May 10, 2024
Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II studyFilipa Lynce, Candace Mainor, Renee N Donahue, et al.
Medrxiv : the Preprint Server for Health Sciences|December 18, 2023
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II studyFilipa Lynce, Candace Mainor, Renee N Donahue, et al.
Nature Communications|March 28, 2024
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II studyFilipa Lynce, Candace Mainor, Renee N Donahue, et al.
Nature Biotechnology|February 5, 2025
Implantation of engineered adipocytes suppresses tumor progression in cancer modelsHai P Nguyen, Kelly An, Yusuke Ito, et al.
The New England Journal of Medicine|April 21, 2021
Sacituzumab Govitecan in Metastatic Triple-Negative Breast CancerAditya Bardia, Sara A Hurvitz, Sara M Tolaney, et al.
Biorxiv : the Preprint Server for Biology|May 20, 2024
Clinicogenomic characterization of inflammatory breast cancerNolan Priedigkeit, Beth Harrison, Robert Shue, et al.
Breast Cancer Research : BCR|January 31, 2024
TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancerFilipa Lynce, Laura E Stevens, Zheqi Li, et al.
Pageof 10

Showing results (81-90 of 96) with videos related to

Sort By:
Pageof 10
European Journal of Cancer (Oxford, England : 1990)|November 1, 2024
Immune checkpoint inhibitors for patients with metastatic triple-negative inflammatory breast cancer (INCORPORATE): An international cohort studyCarmine Valenza, Dario Trapani, Paola Zagami, et al.
Journal of the National Cancer Institute|March 31, 2025
Development of a Multi-Institutional Dataset to Validate a Novel Inflammatory Breast Cancer Diagnostic ScoreFilipa Lynce, Samuel M Niman, Megumi Kai, et al.
JCO Global Oncology|December 20, 2024
Awareness, Knowledge, and Treatment Patterns of Nonmetastatic Inflammatory Breast Cancer in Low- and Middle-Income Countries: The BRIDGES StudyIlana Schlam, Kelly A Hirko, Daniela Shveid, et al.
Nature Communications|May 10, 2024
Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II studyFilipa Lynce, Candace Mainor, Renee N Donahue, et al.
Medrxiv : the Preprint Server for Health Sciences|December 18, 2023
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II studyFilipa Lynce, Candace Mainor, Renee N Donahue, et al.
Nature Communications|March 28, 2024
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II studyFilipa Lynce, Candace Mainor, Renee N Donahue, et al.
Nature Biotechnology|February 5, 2025
Implantation of engineered adipocytes suppresses tumor progression in cancer modelsHai P Nguyen, Kelly An, Yusuke Ito, et al.
The New England Journal of Medicine|April 21, 2021
Sacituzumab Govitecan in Metastatic Triple-Negative Breast CancerAditya Bardia, Sara A Hurvitz, Sara M Tolaney, et al.
Biorxiv : the Preprint Server for Biology|May 20, 2024
Clinicogenomic characterization of inflammatory breast cancerNolan Priedigkeit, Beth Harrison, Robert Shue, et al.
Breast Cancer Research : BCR|January 31, 2024
TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancerFilipa Lynce, Laura E Stevens, Zheqi Li, et al.
Pageof 10